Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Enanta Pharmaceuticals |
---|---|
Information provided by: | Enanta Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00270517 |
This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia
Condition | Intervention | Phase |
---|---|---|
Community Acquired Pneumonia |
Drug: EDP-420 / Duration of Treatment – 3 days Drug: Telithromycin / Duration of Treatment – 7 days |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blinded, Parallel Group, Multicenter Study of EDP-420 Versus Telithromycin for the Treatment of Community Acquired Pneumonia |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Medical Director | clinical@enanta.com |
United States, Massachusetts | |
Enanta Pharmaceuticals, Inc. | Recruiting |
Watertown, Massachusetts, United States, 02472 | |
Contact: Study Director clinical@enanta.com |
Study Director: | Study Director | Enanta Pharmaceuticals, Inc |
Study ID Numbers: | EDP420-05-006 |
Study First Received: | December 23, 2005 |
Last Updated: | September 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00270517 |
Health Authority: | United States: Food and Drug Administration |
Respiratory Tract Infections Respiratory Tract Diseases Lung Diseases Telithromycin Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Pharmacologic Actions |